bioAffinity Technologies, Inc. (BIAF)
Nasdaq: BIAF · Services-Commercial Physical & Biological Research · San Antonio, TX · filing with the SEC since 2017
Who owns bioAffinity Technologies, Inc.
As filed with the SECHolders of 5% or more
1
Richard K. Crumly holds 11.2% of Common Stock, par value $0.007 per share, as its SCHEDULE 13G filed May 14, 2025 says.
Directors and officers
2
report now, of 16 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Richard K. Crumly
SCHEDULE 13G · filed May 14, 2025 · Common Stock, par value $0.007 per share
Bigger Michael
SCHEDULE 13G · filed Oct 1, 2025 · Common Stock, $0.007 par value · reported falling below 5%
What BIAF reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
CyPath Lung
An entity · legal entity · owns, named in the 10-K filed Mar 16, 2026
2 subsidiaries in 1 country, from the list filed with the 10-K filed Apr 1, 2024.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
No open-market trade is on the record for these years.
2022 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.